Home » Stocks » BMRN

BioMarin Pharmaceutical Inc. (BMRN)

Stock Price: $82.30 USD 0.34 (0.41%)
Updated Jun 16, 2021 10:26 AM EDT - Market open
Market Cap 15.07B
Revenue (ttm) 1.84B
Net Income (ttm) 795.09M
Shares Out 181.77M
EPS (ttm) 4.20
PE Ratio 19.60
Forward PE 86.96
Dividend n/a
Dividend Yield n/a
Trading Day June 16
Last Price $82.30
Previous Close $81.96
Change ($) 0.34
Change (%) 0.41%
Day's Open 82.13
Day's Range 81.59 - 82.55
Day's Volume 113,470
52-Week Range 71.35 - 131.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN RAFAEL, Calif., June 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in the BofA Securities 2021 Napa Biopharma Conference on Ju...

1 day ago - PRNewsWire

SAN RAFAEL, Calif., May 27, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences.

2 weeks ago - PRNewsWire

The EMA grants accelerated assessment to BioMarin's (BMRN) request for review of valoctocogene roxaparvovec for treating severe hemophilia A.

3 weeks ago - Zacks Investment Research

We believe that BioMarin Pharmaceutical stock is a good buying opportunity at the present time. BMRN stock trades near $78 currently and it is, in fact, down 19% from its pre-Covid high of around $97 in...

3 weeks ago - Forbes

The European Medicines Agency (EMA) has granted its request for accelerated assessment review to BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) valoctocogene roxaparvovec, gene therapy to treat severe hem...

3 weeks ago - Benzinga

SAN RAFAEL, Calif., May 24, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) has granted its request for accelerated assessment o...

3 weeks ago - PRNewsWire

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced an update to its previously reported results from Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for ad...

3 weeks ago - Benzinga

SAN RAFAEL, Calif., May 19, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results from an open-label Phase 1/2 study of valoctocog...

4 weeks ago - PRNewsWire

SAN RAFAEL, Calif., May 18, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences.

4 weeks ago - PRNewsWire

SAN RAFAEL, Calif., May 12, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced three oral and three poster presentations on valoctocogene roxaparvovec, an investigational g...

1 month ago - PRNewsWire

SAN RAFAEL, Calif., May 3, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences.

1 month ago - PRNewsWire

BioMarin (BMRN) beats estimates for both earnings and revenues in the first quarter of 2021.

1 month ago - Zacks Investment Research

BioMarin (BMRN) delivered earnings and revenue surprises of 75.00% and 9.11%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 79.55% over the past year to $0.09...

1 month ago - Benzinga

SAN RAFAEL, Calif., April 29, 2021 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2021 2020 % Change Total Revenues $ 4...

1 month ago - PRNewsWire

SEATTLE and SAN RAFAEL, Calif., April 28, 2021 /PRNewswire/ -- The Allen Institute and BioMarin Pharmaceutical Inc. announced a collaboration today that will use technologies developed at the Allen Inst...

1 month ago - PRNewsWire

With the trading day about halfway over, each of the major averages had notched a solid gain and was holding just below its respective all-time high.

Other stocks mentioned: ALXN, ATVI, BKR, ESPR, FATE, FLXN, RETA
1 month ago - 24/7 Wall Street

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

SAN RAFAEL, Calif., April 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) presented new and updated data at the 2021 American College of Medical Genetics and Genomics (ACMG) Annual ...

2 months ago - PRNewsWire

SAN RAFAEL, Calif., April 13, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a c...

2 months ago - PRNewsWire

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

SAN RAFAEL, Calif., March 20, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of ...

2 months ago - PRNewsWire

Pharmaceutical stocks are a sector with unique success factors. One factor is developing blockbuster drugs.

Other stocks mentioned: ARGX, BHVN, MRTX, NVO, NVS
3 months ago - InvestorPlace

FDA grants RMAT designation to BioMarin's (BMRN) gene therapy for severe hemophilia A, valoctocogene roxaparvovec, after rejecting it last year.

3 months ago - Zacks Investment Research

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) valoctocogene roxaparvovec investigational gene therapy for the treatment of...

3 months ago - Benzinga

With the trading day about halfway over, the broad markets had managed to push higher on the day, despite dipping into the red earlier.

Other stocks mentioned: GE, ANTM, AOUT, AWK, CRSP, SCHW, WPM ...
3 months ago - 24/7 Wall Street

SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-contro...

3 months ago - PRNewsWire

Biomarin Pharmaceutical (NASDAQ:BMRN) is currently down 7.49% to a price of $78.33. Friday the stock has been traded at a volume of 86.17 thousand, about 7.66% of its recent 30-day volume average of 1.1...

3 months ago - Benzinga

BioMarin (BMRN) beats estimates for both earnings and sales in the fourth quarter. Sales guidance for 2021 falls short of investor expectation.

3 months ago - Zacks Investment Research

Biomarin Pharmaceutical (NASDAQ:BMRN) unveils its next round of earnings this Thursday, February 25. Get prepared with Benzinga's ultimate preview for Biomarin Pharmaceutical's Q4 earnings.

3 months ago - Benzinga

SAN RAFAEL, Calif., Feb. 18, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former ...

3 months ago - PRNewsWire

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

ALXN vs. BMRN: Which Stock Is the Better Value Option?

Other stocks mentioned: ALXN
4 months ago - Zacks Investment Research

ALXN vs. BMRN: Which Stock Is the Better Value Option?

Other stocks mentioned: ALXN
4 months ago - Zacks Investment Research

Shares in this biotech company are down considerably from where they were this summer, but the stock looks ready to take off again.

4 months ago - The Motley Fool

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Intel and BioMarin.

Other stocks mentioned: AVID, IIVI, INTC, UCTT
4 months ago - CNBC

Shares of BioMarin Pharmaceuticals Inc. tumbled 6.6% in trading on Monday, the day after the company shared positive findings from a Phase 3 clinical trial evaluating the experimental drug Roctavian as ...

5 months ago - Market Watch

BioMarin (BMRN) announces one-year update from GENEr8-1 phase III study, which shows that valoctocogene roxaparvovec significantly reduces annualized bleeding rate (ABR) by 84% in patients with hemophil...

5 months ago - Zacks Investment Research

SAN RAFAEL, Calif., Jan. 10, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene rox...

5 months ago - PRNewsWire

Firm also upped FibroGen stake in December

Other stocks mentioned: CREE
5 months ago - GuruFocus

ALXN vs. BMRN: Which Stock Is the Better Value Option?

Other stocks mentioned: ALXN
5 months ago - Zacks Investment Research

Our theme of Out Of Favor Health Care Stocks includes health care names that have witnessed strong growth and improving fundamentals over the last few years but have still underperformed over 2020, part...

Other stocks mentioned: ALKS, IONS
5 months ago - Forbes

Biopharma deal-making is expected to pick up in 2021 after its slump in 2020, with a good example being AstraZeneca's (AZN) nearly $40 billion purchase of Alexion Pharmaceuticals (ALXN), which was annou...

Other stocks mentioned: AMRN
5 months ago - GuruFocus

As markets flirt with record highs, there's more talk about overvalued stocks. However, it's time to consider undervalued stocks.

Other stocks mentioned: AIG, DUK, EPD, SPG, TAP, VMW
5 months ago - InvestorPlace

We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.

Other stocks mentioned: DCPH, QURE, RGNX
5 months ago - Zacks Investment Research

Eli Lilly and Co. (LLY) recently showed its commitment to gene therapy when it signed a deal that could be worth $2.6 billion with Precision BioSciences Inc. (DTIL).

Other stocks mentioned: BLUE
5 months ago - GuruFocus

With 2020 almost over and the new year just two short weeks away, many investors are resetting for what could be a volatile 2021.

Other stocks mentioned: BMY, LLY, MCK, REGN
6 months ago - 24/7 Wall Street

These are the biotech stocks with the best value, fastest growth, and most momentum for Q1 2021.

Other stocks mentioned: BDSI, CPRX, INVA, NVAX, VRTX, VXRT, VYGR
6 months ago - Investopedia

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?

6 months ago - Zacks Investment Research

New York, New York--(Newsfile Corp. - November 24, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between ...

6 months ago - Newsfile Corp

About BMRN

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise ... [Read more...]

Industry
Biotechnology
IPO Date
Jul 23, 1999
CEO
Jean-Jacques Bienaime
Employees
3,059
Stock Exchange
NASDAQ
Ticker Symbol
BMRN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 23 analysts, the average rating for BMRN stock is "Buy." The 12-month stock price forecast is 107.00, which is an increase of 30.01% from the latest price.

Price Target
$107.00
(30.01% upside)
Analyst Consensus: Buy